SPS
AQST icon

Susquehanna Portfolio Strategies’s Aquestive Therapeutics AQST Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,531
Closed -$59.5K – 833
2025
Q1 		$59.5K Buy
+20,531
New +$62.2K 0.03% 158

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna Portfolio Strategies's AQST Position: Q2 2025 in Review

Susquehanna Portfolio Strategies sold out of Aquestive Therapeutics (AQST) in Q2 2025, closing a stake of 20,531 shares — an estimated $59.5K sold.

Susquehanna Portfolio Strategies first reported a position in AQST in Q1 2025 and held it in 1 quarter. The position peaked at $59.5K in Q1 2025. 116 funds tracked by Wall St. Rank hold AQST as of Q2 2025.

  • Susquehanna Portfolio Strategies reported no remaining Aquestive Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 20,531 Aquestive Therapeutics shares in Q2 2025, an estimated $59.5K.
  • Susquehanna Portfolio Strategies first reported a position in Aquestive Therapeutics in Q1 2025 and held it in 1 quarter.
  • Susquehanna Portfolio Strategies's Aquestive Therapeutics position peaked at $59.5K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.